Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 8.01, 9.01 · 8-K

Keenova Therapeutics plc

Other Events

Item 8.01 Other Events. Spin-off of Par Health On October 21, 2025, the Board of Directors (the “Board”) of Mallinckrodt plc (the “Company” or “Mallinckrodt”) approved resolutions authorizing, in principle, the previously announced plan to spin off (the “Spin-off”) the Company’s generic pharmaceuticals, active pharmaceutical ingredients (APIs) and sterile injectables businesses to the Company’s shareholders.…

Filed Oct 24, 2025Accepted Oct 24, 2025, 5:09 PM EDTCIK 1567892Accession 0001104659-25-102199
Share

Company context

Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives. Keenova’s rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.

Recent company filings

  1. 10-Q filingAug 11, 2026
  2. Results of Operations and Financial ConditionAug 11, 2026
  3. Other EventsAug 3, 2026
  4. 4 filingJul 23, 2026
  5. 4 filingJul 23, 2026

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. Spin-off of Par Health On October 21, 2025, the Board of Directors (the “Board”) of Mallinckrodt plc (the “Company” or “Mallinckrodt”) approved resolutions authorizing, in principle, the previously announced plan to spin off (the “Spin-off”) the Company’s generic pharmaceuticals, active pharmaceutical ingredients (APIs) and sterile injectables businesses to the Company’s shareholders. At the time of the Spin-off, such businesses will be held by Par Health, Inc. (“Par Health”), a Delaware corporation and a wholly owned subsidiary of Mallinckrodt. Par Health will operate as an independent company following the Spin-off and its shares will not be listed on a securities exchange. The Spin-off remains subject to the satisfaction of certain conditions, including, among others, the publication of an information statement (the “Information Statement”) regarding the Spin-off and final approval by the Board. The Information Statement is expected to be furnished with the U.S. Securities and Exchange Commission in the coming days. The Board retains the authority to modify the terms of, or to abandon, the Spin-off at any time and for any reason until it has been consummated, including by accelerating or delaying the timing of the consummation of all or part of the Intended Redemption (as defined below). If approved, the Spin-off will be implemented by way of a redemption (the “Intended Redemption”) of all of Mallinckrodt’s issued and outstanding preferred shares, par value $0.001 per share (the “Mallinckrodt Preferred Shares”), comprising 1,796,196,578,472 Mallinckrodt Preferred Shares, upon which the Mallinckrodt Preferred Shares will automatically be cancelled and will no longer be outstanding. At the closing of the Intended Redemption, the Mallinckrodt Preferred Shares will be redeemed in exchange for the following, subject to compliance with the Certification Procedures (as defined below) and the terms of the Intended Redemption (the “Redemption Consideration”): in the case of Qualified Shareholders (as defined below), the right to receive a certain number of shares of common stock, par value $0.01 per share, of Par Health (the “Par Health Common Stock”), for each Mallinckrodt Preferred Share; or in the case of Non-Qualified Shareholders (as defined below), the right to receive a certain amount of cash for each Mallinckrodt Preferred Share that the Board determines is equal in value to the Par Health Common Stock allocated to Qualified Shareholders for each Mallinckrodt Preferred Share. As is described in the Notice of Intention to Redeem (as defined below): a “Qualified Shareholder” is a holder of Mallinckrodt Preferred Shares as of the Record Date (as defined below), as reflected in the Mallinckrodt Register of Members (each, a “Record Holder”) (and/or beneficial holders identified by a Record Holder that is a broker, bank or similar organization as the beneficial holders of Mallinckrodt Preferred Shares held by such Record Holder in such capacity on the Record Date (each, a “Street Name Holder”)) that has complied with the Certification Procedures and that has returned a Certification Form, duly, truthfully and accurately completed and validly executed in accordance with the instructions thereto, certifying (among other things) that such Record Holder or Street Name Holder (as the case may be) is a qualified institutional buyer as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) (a “Qualified Institutional Buyer”), an institutional accredited investor (an “accredited investor” as defined in clauses (1), (2), (3), (7), (8), (9), (12) and (13) of Rule 501(a) under the Securities Act) (an “Institutional Accredited Investor”) or a director or officer of the Company or Par Health as of the Intended Redemption who is also an accredited investor (as defined in Rule 501(a) under the Securities Act); and a “Non-Qualified Shareholder” is Record Holder or Street Name Holder as of the Record Date that has complied with the Certification Procedures and that has returned a Certification Form, duly, truthfully and accurately completed and validly executed in accordance with the instructions thereto, certifying (among other things) that such Record Holder or Street Name Holder (as the case may be) is not a Qualified Shareholder. ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── -2- The record date for determining the holders of the Mallinckrodt Preferred Shares entitled to the Redemption Consideration will be 5:30 p.m. (Eastern Time in the United States) on October 27, 2025 (the “Record Date”). As will be described in greater detail in the Information Statement, one hundred percent (100%) of the Par Health Common Stock will be allocated to Qualified Shareholders in connection with the Spin-off. As a result, the ownership of Par Health following the Spin-off will depend on the outcome of the Certification Procedures. Depending on the number of Mallinckrodt Preferred Shares held by Qualified Shareholders relative to the number of Mallinckrodt Preferred Shares held by Non-Qualified Shareholders (or shareholders who do not return the Certification Forms in accordance with the Certification Procedures within one year following the Spin-off), individual Qualified Shareholders may hold a greater percentage of the issued and outstanding Par Health Common Stock relative to their current ownership of Mallinckrodt Preferred Shares. Similarly, the amount of cash allocated to Non-Qualified Shareholders in exchange for each Mallinckrodt Preferred Share will increase with the concentration of Par Health ownership to provide such Non-Qualified Shareholders with equal value per share (as determined by the Board), as described above. The Par Health Common Stock to be allocated in connection with the Spin-off has not been and will not be registered under the Securities Act or the Securities Exchange Act of 1934, as amended. Notice of Intention to Redeem On October 24, 2025, the Company issued a notice of intention to redeem (the “Notice of Intention to Redeem”), reflecting its non-binding intention to acquire, by way of the Intended Redemption, all of the issued and outstanding Mallinckrodt Preferred Shares. The proposed terms of the Intended Redemption are set out in greater detail in the Notice of Intention to Redeem. Subject to the approval of the Board, the date of consummation of the Intended Redemption (the “Redemption Date”) will be November 10, 2025, or such other date as may be determined by the Board in its sole and absolute discretion in accordance with the Company’s articles of association and the terms of the Mallinckrodt Preferred Shares adopted pursuant to the approval by the Board on September 10, 2025. The Company is not obligated to proceed with the Intended Redemption and the Board may abandon the Intended Redemption at any time prior to the Redemption Date. If the Company is to proceed with the Intended Redemption on the Redemption Date, a notice of redemption will be sent to all holders of Mallinckrodt Preferred Shares effecting the Intended Redemption (the “Redemption Notice”). The Intended Redemption will be conditional on the issuance of the Redemption Notice and subject always to the terms of the Redemption Notice. This summary does not purport to be complete and is qualified in its entirety by reference to the terms of the Intended Redemption set out in further detail in the Notice of Intention to Redeem, a copy of which will be included in the Information Statement and is attached as Exhibit 99.2 to this Current Report on Form 8-K. Certification Procedures Required for Shareholders to Receive Par Health Common Stock or Cash As will be described in greater detail in the Information Statement, eligible shareholders must, among other things, properly and timely complete the following documents (the “Certification Procedures”) to receive the Redemption Consideration: Certification Form: A certification form (a “Certification Form”) to be made available by the Redemption Agent (as defined below) that requires each Record Holder (and/or Street Name Holder, where applicable) to certify, among other things, whether such person is a Qualified Shareholder or a Non-Qualified Shareholder; and Tax Form: Such other documents as may reasonably be required by the Company, on the one hand, or Computershare, Inc. or Computershare Trust Company, N.A., the Company’s certification and redemption agent (the “Redemption Agent”), on the other hand, including a validly executed appropriate Internal Revenue Service (“IRS”) Form W-8 or IRS Form W-9, as applicable, and any other documentation and attachments as may be required to establish that any payment made to such Qualified Shareholder or Non-Qualified Shareholder (and any Record Holder that is a bank, brokerage firm or similar organization receiving such payment for the benefit of such Qualified Shareholder or Non-Qualified Shareholder, if applicable) is not subject to U.S. backup withholding tax. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── -3- The Company will begin accepting Certification Forms following the publication of the Information Statement. Certification Forms will be available electronically through an online portal (the “Certification Portal”) maintained by the Redemption Agent. Record Holders will have direct access to the Certification Portal through a hyperlink provided in the Information Statement, and will also have the option to return a paper Certification Form upon request. The Company is providing a sample Certification Form on this Current Report on Form 8-K in order to facilitate the prompt completion of the Certification Procedures once the Company begins accepting Certification Forms. Street Name Holders may only access the Certification Portal through a unique hyperlink provided by their bank, brokerage firm or similar organization. Street Name Holders should immediately contact their bank, brokerage firm or similar organization to ensure they are able to obtain access to the Certification Portal. A shareholder’s entitlement to the Redemption Consideration in the Intended Redemption will lapse and expire if such shareholder does not accurately and timely return a Certification Form, in accordance with the instructions set forth in the Information Statement, and otherwise comply with the Certification Procedures within one year following the Spin-off. For the avoidance of doubt, the Certification Form is not an “election” form and shareholders do not have a choice between the right to receive Par Health Common Stock or cash in the Intended Redemption. Whether the Certification Procedures have been complied with in any specific case or generally will be determined by Mallinckrodt in its sole and absolute discretion. Mallinckrodt or the Redemption Agent may reject, question or modify any Certification Form for any reason. SHAREHOLDERS ARE URGED TO COMPLETE THEIR CERTIFICATION FORMS AS SOON AS POSSIBLE FOLLOWING PUBLICATION OF THE INFORMATION STATEMENT. IF MALLINCKRODT HAS NOT RECEIVED VALID CERTIFICATION FORMS FROM QUALIFIED SHAREHOLDERS (OR PERSONS THAT ARE EXPECTED TO BE QUALIFIED SHAREHOLDERS UPON THE SATISFACTION OF THE REMAINING CERTIFICATION PROCEDURES OTHER THAN THE RETURN OF A CERTIFICATION FORM) HOLDING AT LEAST A SPECIFIED PERCENTAGE (EXPECTED TO BE APPROXIMATELY 75%) (OR SUCH GREATER OR LESSER PERCENTAGE AS MAY BE DETERMINED BY THE BOARD IN ITS SOLE AND ABSOLUTE DISCRETION) OF MALLINCKRODT PREFERRED SHARES OUTSTANDING ON THE RECORD DATE BY 5:30 P.M. (EASTERN TIME IN THE UNITED STATES) ON NOVEMBER 7, 2025 (OR SUCH OTHER DATE AS MAY BE DETERMINED BY THE BOARD IN ITS SOLE AND ABSOLUTE DISCRETION), THE BOARD MAY DETERMINE NOT TO PROCEED WITH THE SPIN-OFF. Only Record Holders and Street Name Holders as of the Record Date (i.e., October 27, 2025) that properly comply with the Certification Procedures (as described above) will be eligible to receive the Par Health Common Stock or cash, as applicable. Shareholders may transfer Par Health Common Stock following the closing of the Intended Redemption, subject to compliance with applicable securities laws and the transfer limitations set forth in Par Health’s organizational documents. Note that Par Health’s organizational documents will only permit transfers of Par Health Common Stock to a Qualified Institutional Buyer, Institutional Accredited Investor or director or officer of Par Health who also is an accredited investor. Closing of the Mallinckrodt Register of Members In accordance with section 174 of The Companies Act 2014 of Ireland, as amended, the Board closed the Mallinckrodt Register of Members with effect from 5:00 p.m. (Eastern Time in the United States) on October 23, 2025 until the earlier of (i) 5:00 p.m. (Eastern Time in the United States) on November 22, 2025 or (ii) such earlier date as may be notified by the Company. Mallinckrodt published notice of the closing of the Mallinckrodt Register of Members in the Irish Times and the Wall Street Journal on October 22, 2025. Transfers of shares in the capital of the Company will not be registered while the Mallinckrodt Register of Members is closed regardless of when any such transfer may have occurred. -4- This summary of the Spin-off, the Intended Redemption and the Certification Procedures does not purport to be complete. The Spin-off, the Intended Redemption and the Certification Procedures will be outlined in greater detail in the Information Statement. Questions and Assistance Mallinckrodt shareholders with questions are directed to contact the appropriate resource below. For assistance with the Certification Procedures (including completion of the Certification Form), shareholders should contact Mallinckrodt’s shareholder liaison, Innisfree M&A Incorporated, at (888) 750-9498. Innisfree will advise all Street Name Holders to contact their bank, broker or similar organization immediately to ensure they are able to obtain access to the Certification Portal. For assistance with share transfer procedures, verifying holdings of Mallinckrodt Preferred Shares in Computershare US and other inquiries, shareholders should contact Mallinckrodt’s information agent, Georgeson, at (866) 585-7241 (toll free), (310) 853-6676 (outside the U.S.) or MallExchange@Georgeson.com. Only Record Holders have an account with Computershare US. Street Name Holders should contact their bank, broker or similar organization for assistance. For Computershare US account assistance, shareholders should contact Computershare US at (866) 644-4127 (toll free) or (781) 575-2906 (outside the U.S. or Canada). Only Record Holders have an account with Computershare US. Street Name Holders should contact their bank, broker or similar organization for assistance. For other inquiries, shareholders should contact Mallinckrodt’s Corporate Secretary’s Office at corporate.secretary@mnk.com.
Filed exhibits (2)
EX-99.1 (by filename) tm2529406d1_ex99-1.htm

EX-99.1 2 tm2529406d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROMPT ACTION IS REQUIRED BY ALL BROKERS AND SHAREHOLDERS PLEASE RETURN THIS CERTIFICATION FORM IMMEDIATELY FAILURE TO PROPERLY AND TIMELY COMPLETE THIS CERTIFICATION FORM IN ACCORDANCE WITH THE INSTRUCTIONS IN THE INFORMATION STATEMENT WILL RESULT IN YOUR RIGHT TO RECEIVE PAR HEALTH COMMON STOCK OR CASH IN THE SPIN-OFF LAPSING AND EXPIRING Spin-off of Par Health On October 10, 2025, Mallinckrodt plc (“Mallinckrodt”) issued a total of 1,796,196,578,472 preferred shares, par value US$0.001 per share of Mallinckrodt (each, a “Mallinckrodt Preferred Share”). 45,564 Mallinckrodt Preferred Shares were issued for each outstanding ordinary share of Mallinckrodt to ordinary shareholders of record as of the close of business on October 8, 2025 (Eastern Time in the United States). As a result of this issuance, you are the record holder of Mallinckrodt Preferred Shares. On October 21, 2025, the Mallinckrodt Board of Directors (the “Board”) approved resolutions authorizing, in principle, the previously announced plan to spin off (the “Spin-off”) Mallinckrodt’s generic pharmaceuticals, active pharmac…

Open exhibit ↗
EX-99.2 (by filename) tm2529406d1_ex99-2.htm

EX-99.2 3 tm2529406d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MALLINCKRODT PLC (in the process of changing its name to Keenova Therapeutics plc) (the “Company”) College Business & Technology Park Cruiserath, Blanchardstown, Dublin 15, Ireland NOTICE OF INTENTION TO REDEEM 2025 PREFERRED SHARES OF THE COMPANY To: The Holders of the 2025 Preferred Shares (as defined below) as at the Record Date (as defined below) Date: October 24, 2025 Dear Holders, We refer to the 2025 Preferred Shares of the Company of USD$0.001 each issued on or around October 10, 2025 (the “2025 Preferred Shares”), governed by the terms adopted pursuant to the resolutions of the board of directors of the Company on September 10, 2025 (the “Terms”), as filed with the Companies Registration Office of Ireland, a copy of which is available on the Company’s investor relations website at https://ir.mallinckrodt.com/financial-information/sec-filings. This notice constitutes a Notice of Intention to Redeem within the meaning of the Terms, and this notice shall be construed in accordance with the Terms, including the expressions defined therein, unless otherwise defined herein or in Appendix 1 h…

Open exhibit ↗